Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

May 26, 2015

Primary Completion Date

October 31, 2017

Study Completion Date

June 18, 2019

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Selumetinib

DRUG

Pemetrexed

DRUG

Cisplatin

DRUG

Carboplatin

Trial Locations (12)

T2N 4N2

Tom Baker Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

V2S 0C2

BCCA - Abbotsford Centre, Abbotsford

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

E2L 4L2

Regional Health Authority B, Zone 2, Saint John

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 5P9

Cancer Centre of Southeastern Ontario at Kingston, Kingston

L1G 2B9

Lakeridge Health Oshawa, Oshawa

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

M5G 1X5

Mount Sinai Hospital, Toronto

M5G 2M9

University Health Network, Toronto

H2L 4M1

CHUM - Hopital Notre-Dame, Montreal

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Canadian Cancer Trials Group

NETWORK